Director Dealing

RNS Number : 3649W

Destiny Pharma PLC

23 April 2021

 

Destiny Pharma plc

("Destiny Pharma" or the "Company")

Director Dealing

Brighton, United Kingdom - 23 April 2021 - Destiny Pharma plc (AIM: DEST) a clinical stage innovative biotechnology company focused on the development of novel medicines that can prevent life threatening infections, announces that it was notified on 22 April 2021 that on that same day, Nick Rodgers, Chairman of the Company, purchased 5,000 Ordinary Shares at a price of 158p per Ordinary Share. Following the transaction his total beneficial interest is 52,462 Ordinary Shares, representing 0.09% of the total issued share capital of the Company.

Details of the full notification received by the Company are set out below:

1.	Details of the person discharging managerial responsibilities / person closely associated
a)	Name	Nick Rodgers
2.	Reason for the Notification
a)	Position/status	Chairman
b)	Initial notification/Amendment	Initial notification
3.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	Destiny Pharma plc
b)	LEI	213800O9WH9Z38EHAC95
4.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the Financial instrument, type of instrument	Ordinary Shares of 1 pence each in Destiny Pharma plc
	Identification code	DEST    GB00BDHSP575
b)	Nature of the transaction	Purchase of Ordinary Shares
c)	Price(s) and volume(s)	158 pence per Ordinary Share 5,000 Ordinary Shares
d)	Aggregated information: Aggregated volume Price	See 4c) above
e)	Date of the transaction	22 April 2021
f)	Place of the transaction	London Stock Exchange, AIM Market

Enquiries:

Destiny Pharma plc	[phone]
Neil Clark (Chief Executive Officer) Shaun Claydon (Chief Financial Officer and Company Secretary)
finnCap Limited - Nominated Adviser and Joint Broker	[phone]
Geoff Nash / Kate Bannatyne / Charlie Beeson (Corporate Finance) Alice Lane (ECM)
WG Partners LLP - Joint Broker	[phone]
Nigel Barnes / Claes Spång / Nigel Birks / Andrew Craig
Optimum Strategic Communications	[phone]
Mary Clark / Shabnam Bashir / Manel Mateus

The information communicated in this announcement contains inside information for the purposes of Article 7 of the Market Abuse Regulation (EU) No. 596/2014.

About Destiny Pharma

Destiny Pharma is a clinical stage, innovative biotechnology company focused on the development of novel medicines that can prevent life-threatening infections. Its pipeline has novel microbiome-based biotherapeutics and XF drug clinical assets including NTCD-M3, a Phase 3 ready treatment for the prevention of C. difficile infection (CDI) recurrence which is the leading cause of hospital acquired infection in the US and also XF-73 nasal gel, which is in a Phase 2b clinical trial targeting the prevention of post-surgical Staphylococcal hospital including MRSA. It is also co-developing SPOR-COV, a novel, biotherapeutic product for the prevention of COVID-19 and other viral respiratory infections and has earlier grant funded XF research projects.

For further information, please visit  https://www.destinypharma.com

 

END

 

 

DSHFLFLRSFIFFIL